Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PARSIPPANY, N.J., April 03, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 16th Annual Needham Healthcare Conference at 3:00 PM ET on Tuesday, April 4, 2017, in New York.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
